Viyash Scientific Limited has received the necessary regulatory approval from Italian authorities for its proposed acquisition of BioForLife Italia S.r.l. This development, following earlier disclosures, marks a significant step towards completing the 100% shareholding acquisition by its subsidiary, Alivira Animal Health Limited. The expected timeline for the transaction’s completion has now been revised and is anticipated within two months from the date of this intimation.
Key Regulatory Approval Secured for Italian Acquisition
Viyash Scientific Limited announced today that it has obtained the requisite approval from the relevant Italian authorities concerning its proposed acquisition of BioForLife Italia S.r.l. This critical clearance is in line with the applicable Italian FDI / Golden Power regulations.
Revised Deal Timeline
This announcement follows previous disclosures made on June 8, 2026, and July 21, 2026, regarding the planned 100% shareholding acquisition of BioForLife Italia S.r.l. by Alivira Animal Health Limited, an Ireland-based step-down wholly owned subsidiary of Viyash Scientific Limited. Taking into account the remaining customary closing formalities and conditions, the company has revised the expected timeline for the transaction’s completion. The deal is now anticipated to be finalized within two months from the date of this intimation.
Terms Remain Unchanged
Except for the regulatory approval obtained and the revised completion timeline, all other material terms and conditions of the transaction, as previously disclosed, remain unchanged. Viyash Scientific Limited has requested that these updates be taken on record.
Source: BSE
